Ordesekimab structure
|
Common Name | Ordesekimab | ||
|---|---|---|---|---|
| CAS Number | 879293-15-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OrdesekimabOrdesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD)[1]. |
| Name | Ordesekimab |
|---|
| Description | Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD)[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-15 |
| In Vitro | The simultaneous binding of Ordesekimab (AMG 714) to the Fcγ receptor (R) IIIα expressed on natural killer (NK) cells and to the IL-15/IL-15Rα complex on cells such as monocytes may theoretically enable antibody-dependent cell-mediated cytotoxicity (ADCC) toward the IL-15Rα-expressing cells[1]. |
| References |
| No Any Chemical & Physical Properties |